We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £153,441
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
Plant-based diets, health and fitness programmes for those interested in veganism to improve their health and wellbeing. Skinny Bitch's book has sold more than 1.1m copies and is available in 6 languages. Readers of the book include celebrities such as Eva Longoria and Jessica Alba. Ellen DeGeneres has stated that the Skinny Bitch book is the reason she became vegan. The company is now expanding their brand further by offering their content through online guides and blogs. Skinny Bitch is also intending to generate revenue via vegan supplements produced in the US to be sold through their website and third party e-commerce channels.
days to go: Expired investment: £75,810
VULSINI operates in the ‘Health & Wellness’ sector, and supplies massage related equipment to spas, hotels, colleges, massage therapists and a wide network of distributors worldwide.
days to go: Expired investment: £23,940
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go: Expired investment: £768,597
StrongHer empowers and educates women of ALL socio-demographics and diversities to control their wellbeing, nutrition, and fitness. It is an established brand known as a top workout class by London Living. The brand has a social following of more than 13,000 across Facebook and Instagram. StrongHer fills the gap between boutique fitness establishments and budget gyms to give accessible courses, classes, social events, and workshops. In 2018, the company held its first ‘fitness festival’ - Ultimate Warrior Weekend which was attended by around 100 women. With the proceeds, the company will create its first strength and conditioning facility for women.
days to go: Expired investment: £126,730
PCL Health is a Business-to-Business (B2B) Software-as-a-Service (SaaS) entity that aims to bring hospital-level care to anyone remotely. It asserts that the correct use of remote monitoring can reduce mortality by up to 45%. PCL Health intends to become a contender in the remote healthcare market that is set to touch $30 billion by 2023. It has developed CE rated medical-grade devices that use health algorithms combined with sensors and its proprietary range of apps to allow family members to proactively monitor the health of their loved ones, alongside carers and doctors, remotely. PCL Health has completed two pilots with 65 people and received a Letter Of Intent (LOI) from a National Health Service (NHS) Trust for a clinical trial. It won the 'Innovative Startup' competition at the 2019 Healthcare Unblocked event. PCL Health will use the investment for technology enhancement, running further pilot studies, and working capital.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £394,680
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph